SI-BONE, Inc.
General ticker "SIBN" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $692.5M (TTM average)
SI-BONE, Inc. follows the US Stock Market performance with the rate: 24.6%.
Estimated limits based on current volatility of 1.7%: low 19.39$, high 20.08$
Factors to consider:
- Total employees count: 376 (+7.7%) as of 2025
- US accounted for 95.1% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Market competition, Regulatory and compliance, Supply chain disruptions, Labor/talent shortage/retention, Manufacturing failures
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [15.03$, 26.72$]
- 2026-12-31 to 2027-12-31 estimated range: [15.10$, 26.97$]
Financial Metrics affecting the SIBN estimates:
- Positive: with PPE of -45.9 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of -0.08 <= 2.37
- Negative: negative Net income
- Negative: 0.41 < Inventory ratio change, % of 0.50
- Positive: -13.52 < Operating profit margin, % of -10
- Negative: 0.47 < Industry inventory ratio change (median), % of 0.70
- Negative: Industry earnings per price (median), % of -3.46 <= 0
- Negative: 69.38 < Shareholder equity ratio, % of 74.42 <= 81.92
- Negative: negative Industry operating cash flow (median)
- Negative: 0.07 < Interest expense per share per price, % of 0.30
- Positive: -0.14 < Investing cash flow per share per price, % of 0.47
Short-term SIBN quotes
Long-term SIBN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $138.89MM | $167.18MM | $200.93MM |
| Operating Expenses | $185.82MM | $202.43MM | $223.25MM |
| Operating Income | $-46.93MM | $-35.25MM | $-22.33MM |
| Non-Operating Income | $3.60MM | $4.33MM | $3.43MM |
| Interest Expense | $3.46MM | $3.44MM | $2.63MM |
| R&D Expense | $15.03MM | $16.56MM | $17.45MM |
| Income(Loss) | $-43.34MM | $-30.91MM | $-18.90MM |
| Net Income(Loss)* | $-43.34MM | $-30.91MM | $-18.91MM |
| Stockholders Equity | $169.38MM | $166.96MM | $177.53MM |
| Inventory | $20.25MM | $27.07MM | $33.90MM |
| Assets | $230.43MM | $230.44MM | $238.56MM |
| Operating Cash Flow | $-18.71MM | $-12.43MM | $-0.68MM |
| Capital expenditure | $7.80MM | $10.50MM | $8.41MM |
| Investing Cash Flow | $-59.80MM | $12.62MM | $4.16MM |
| Financing Cash Flow | $90.93MM | $1.96MM | $3.38MM |
| Earnings Per Share** | $-1.13 | $-0.75 | $-0.43 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.